NBSE - NeuBase Therapeutics GAAP EPS of -$0.13 misses by $0.02
- NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.13 misses by $0.02 .
- As of December 31, 2022, the Company had cash and cash equivalents of approximately $17.4 million, compared with approximately $23.2 million as of September 30, 2022.
- NeuBase estimates its current cash and cash equivalents are sufficient to fund currently planned operating and capital expenditures into the second quarter of calendar year 2024.
- Shares +2.65% .
For further details see:
NeuBase Therapeutics GAAP EPS of -$0.13 misses by $0.02